Exploration of potential targets and mechanisms of naringenin in the treatment of nonalcoholic fatty liver disease through network pharmacology

被引:2
|
作者
Yu, Chenyang [1 ]
Han, Duan [2 ]
Yu, Jingfang [2 ]
Zhu, Ran [1 ]
Zhu, Cuiyan [1 ]
Wang, Fule [1 ]
Zhang, Tiefeng [1 ]
机构
[1] Shandong Univ Tradit Chinese Med, First Sch Clin Med, Jinan 250013, Shandong, Peoples R China
[2] Shandong Univ Tradit Chinese Med, Affiliated Hosp 2, Jinan, Shandong, Peoples R China
关键词
mechanisms; naringenin; network pharmacology; nonalcoholic fatty liver disease; targets; INSULIN-RESISTANCE; RISK-FACTORS; DOUBLE-BLIND; INFLAMMATION; INHIBITION; MODELS;
D O I
10.1097/MD.0000000000035460
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: This study aimed to use network pharmacology to investigate the molecular mechanisms and potential targets of naringenin (NR) for nonalcoholic fatty liver disease (NAFLD) treatment to offer new drug development ideas. Methods: The structure and compound information of NR were obtained from PubChem and the traditional Chinese medicine system pharmacology database and analysis platform. The traditional Chinese medicine system pharmacology database and analysis platform Database, Comparative Toxicogenomics Database and Encyclopedia of Traditional Chinese Medicine Database were then used to predict the related targets of NR. Online mendelian inheritance in man, Disgenet, Gene cards, The therapeutic target database and Drug bank were used to screen NAFLD targets, and the intersection analysis was performed with the targets of NR active components to obtain the targets of NR in the treatment of NAFLD. The protein-protein interaction network of therapeutic targets was constructed by protein-protein interaction networks functional enrichment analysis 11.0, and gene ontology (GO) functional enrichment analysis and Kyoto encyclopedia of genes and genomes pathway enrichment analysis of therapeutic targets was performed by Metascape platform. Results: In this study, 171 NR targets and 1748 potential targets of NAFLD were screened, and 89 crossover targets and 16 core targets were screened and finally obtained. A total of 176 GO items were obtained by GO enrichment analysis (P<.05), including 389 biological process, 6 cell composition and 30 molecular function. A total of 137 signaling pathways were obtained by Kyoto encyclopedia of genes and genomes pathway enrichment and screening (P<.05). The core targets of NR in the treatment of NAFLD are TP53, CASP3, PRKCA, AKT1, RELA, PPARG, NCOA2, CYP1A1, ESR1, MAPK3, STAT3, JAK1, MAPK1, TNF, PPARA and PRKCB. Enrichment analysis showed that NR mainly involved in biological processes such as cellular response to nitrogen compound, regulation of miRNA transcription and negative regulation of miRNA-mediated gene silencing. It regulates Hepatitis B, Lipid and atherosclerosis, cytomegalovirus infection, Hepatitis C, AGE-RAGE signaling pathway in diabetic patients complications and other ways play a role in the treatment of NAFLD. Conclusions: The therapeutic effect of NR on NAFLD has the characteristics of multi-targets and multi-pathways, which provides a preliminary theoretical basis for clinical trials and the development of new drugs.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Novel therapeutic targets for nonalcoholic fatty liver disease
    Eguchi, Akiko
    Povero, Davide
    Alkhouri, Naim
    Feldstein, Ariel E.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (07) : 773 - 779
  • [32] The lipidome in nonalcoholic fatty liver disease: actionable targets
    Pirola, Carlos J.
    Sookoian, Silvia
    JOURNAL OF LIPID RESEARCH, 2021, 62
  • [33] Exploring the mechanism of PingTang No.5 capsule on nonalcoholic fatty liver disease through network pharmacology and experimental validation
    Hung, Tzu-Chieh
    Zhao, Nengjiang
    Huang, Caoxin
    Liu, Suhuan
    Liu, Tao
    Huang, Wenfang
    Xu, Xiangbin
    Ji, Zhi-Liang
    Yang, Shuyu
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 138
  • [34] Nanoliposome improves inhibitory effects of naringenin on nonalcoholic fatty liver disease in mice
    Chen, Cong
    Jie, Xu
    Ou, Yangjie
    Cao, Yini
    Xu, Lu
    Wang, Yunxia
    Qi, Rong
    NANOMEDICINE, 2017, 12 (15) : 1791 - 1800
  • [35] A Network Pharmacology Study on the Active Components and Targets of the Radix Ginseng and Radix Bupleuri Herb Pair for Treating Nonalcoholic Fatty Liver Disease
    Zhang, Qiang
    Zhang, Li
    Liu, Kaili
    Shang, Haonan
    Ruan, Jun
    Yu, Zhonghai
    Meng, Shengxi
    Liang, Fang
    Wang, Tianzhan
    Zhang, Hongyan
    Peng, Wenbo
    Wang, Yuxin
    Chen, Junming
    Xiao, Tiegang
    Wang, Bing
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [36] Exploration of the Potential Mechanisms of Wumei Pill for the Treatment of Ulcerative Colitis by Network Pharmacology
    Huang, Jinke
    Zheng, Yijun
    Ma, Jinxin
    Ma, Jing
    Lu, Mengxiong
    Ma, Xiangxue
    Wang, Fengyun
    Tang, Xudong
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2021, 2021
  • [37] Investigation of the potential mechanism of the Shugan Xiaozhi decoction for the treatment of nonalcoholic fatty liver disease based on network pharmacology, molecular docking and molecular dynamics simulation
    Yang, Rong
    Yang, Huili
    Jiang, Dansheng
    Xu, Linyi
    Feng, Lian
    Xing, Yufeng
    PEERJ, 2022, 10
  • [38] Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies
    Sunny, Nishanth E.
    Bril, Fernando
    Cusi, Kenneth
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2017, 28 (04): : 250 - 260
  • [39] Exploration of Shared Gene Signatures and Molecular Mechanisms Between Periodontitis and Nonalcoholic Fatty Liver Disease
    Xu, Wanqiu
    Zhang, Zhengwei
    Yao, Lihong
    Xue, Bing
    Xi, Hualei
    Wang, Xiumei
    Sun, Shibo
    FRONTIERS IN GENETICS, 2022, 13
  • [40] Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms
    Moller, Soren
    Kimer, Nina
    Kronborg, Thit
    Grandt, Josephine
    Hove, Jens Dahlgaard
    Barlose, Mads
    Gluud, Lise Lotte
    SEMINARS IN LIVER DISEASE, 2021, 41 (03) : 235 - 247